[go: up one dir, main page]

WO2006085033A3 - Compositions pharmaceutiques destinees au traitement du cancer de la prostate - Google Patents

Compositions pharmaceutiques destinees au traitement du cancer de la prostate Download PDF

Info

Publication number
WO2006085033A3
WO2006085033A3 PCT/FR2006/050117 FR2006050117W WO2006085033A3 WO 2006085033 A3 WO2006085033 A3 WO 2006085033A3 FR 2006050117 W FR2006050117 W FR 2006050117W WO 2006085033 A3 WO2006085033 A3 WO 2006085033A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prostate cancer
pharmaceutical compositions
pharmaceutical composition
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/050117
Other languages
English (en)
Other versions
WO2006085033A2 (fr
Inventor
Olivier Cussenot
Guy Vallancien
Gaelle Fromont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE DE RECHERCHE POUR LES PATHOLOGIES PROSTATIQUES
CT DE RECH POUR LES PATHOLOGIE
Original Assignee
CENTRE DE RECHERCHE POUR LES PATHOLOGIES PROSTATIQUES
CT DE RECH POUR LES PATHOLOGIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTRE DE RECHERCHE POUR LES PATHOLOGIES PROSTATIQUES, CT DE RECH POUR LES PATHOLOGIE filed Critical CENTRE DE RECHERCHE POUR LES PATHOLOGIES PROSTATIQUES
Priority to EP06709496A priority Critical patent/EP1851549A2/fr
Publication of WO2006085033A2 publication Critical patent/WO2006085033A2/fr
Publication of WO2006085033A3 publication Critical patent/WO2006085033A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant un composé qui régule négativement l'expression de la protéine BCAR-1, en association avec au moins un excipient pharmaceutiquement acceptable. Une telle composition pharmaceutique permet notamment de traiter des cancers de la prostate même lorsque ceux-ci sont devenus résistants aux traitements par des composés antiandrogéniques. L'invention concerne également des procédés de détection, et d'évaluation in vitro de l'agressivité d'un cancer de la prostate.
PCT/FR2006/050117 2005-02-09 2006-02-09 Compositions pharmaceutiques destinees au traitement du cancer de la prostate Ceased WO2006085033A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06709496A EP1851549A2 (fr) 2005-02-09 2006-02-09 Compositions pharmaceutiques destinees au traitement du cancer de la prostate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0550387 2005-02-09
FR0550387A FR2881830B1 (fr) 2005-02-09 2005-02-09 Compositions pharmaceutiques destinees au traitement du cancer de la prostate

Publications (2)

Publication Number Publication Date
WO2006085033A2 WO2006085033A2 (fr) 2006-08-17
WO2006085033A3 true WO2006085033A3 (fr) 2007-01-11

Family

ID=34955116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/050117 Ceased WO2006085033A2 (fr) 2005-02-09 2006-02-09 Compositions pharmaceutiques destinees au traitement du cancer de la prostate

Country Status (3)

Country Link
EP (1) EP1851549A2 (fr)
FR (1) FR2881830B1 (fr)
WO (1) WO2006085033A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006831A2 (fr) * 1997-07-29 1999-02-11 Dorssers Lambert C J Genes de resistance aux carcinomes mammaires, procede de detection et d'utilisation de ces genes r
WO2003068054A2 (fr) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification de marqueurs de tumeur du cancer de l'ovaire et cibles therapeutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006831A2 (fr) * 1997-07-29 1999-02-11 Dorssers Lambert C J Genes de resistance aux carcinomes mammaires, procede de detection et d'utilisation de ces genes r
WO2003068054A2 (fr) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification de marqueurs de tumeur du cancer de l'ovaire et cibles therapeutiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DORSSERS LAMBERT C J ET AL: "The prognostic value of BCAR1 in patients with primary breast cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 SEP 2004, vol. 10, no. 18 Pt 1, 15 September 2004 (2004-09-15), pages 6194 - 6202, XP002391647, ISSN: 1078-0432 *
GAO B ET AL: "Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells.", FEBS LETTERS. 19 JAN 2001, vol. 488, no. 3, 19 January 2001 (2001-01-19), pages 179 - 184, XP002391648, ISSN: 0014-5793 *
NIU HUI-LIN ET AL: "[Recent advances on molecular pathology of prostate carcinoma]", AI ZHENG = AIZHENG = CHINESE JOURNAL OF CANCER. MAY 2003, vol. 22, no. 5, May 2003 (2003-05-01), pages 552 - 556, XP002346170, ISSN: 1000-467X *

Also Published As

Publication number Publication date
EP1851549A2 (fr) 2007-11-07
FR2881830A1 (fr) 2006-08-11
FR2881830B1 (fr) 2007-05-04
WO2006085033A2 (fr) 2006-08-17

Similar Documents

Publication Publication Date Title
WO2006113703A3 (fr) Derives de carboline utiles dans le traitement du cancer
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
IN2012DN01964A (fr)
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
WO2008079988A3 (fr) Quinazolines destinés à l'inhibition de pdk1
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TWI317619B (en) Composition for the improvement of liver function, the reduction of serum ethanol level and antioxidant activity enhancement
WO2007118149A3 (fr) Thiazole et thiophene analogues et leur utilisation pour traiter des maladies auto-immunes et des cancers
JO2848B1 (en) Organic compounds
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
WO2008073899A3 (fr) Compositions associées à prrg4 et procédés d'utilisation de celles-ci dans des procédés de diagnostic de tumeur
WO2007053573A3 (fr) Traitement du cancer au moyen de sorafenib
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
WO2008002672A3 (fr) Cibles utilisées pour le diagnostic, le pronostic et la thérapie du cancer
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire
WO2006089087A9 (fr) Compositions, trousses et methodes servant a effectuer l'identification, l'evaluation, la prophylaxie et la therapie du cancer
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2007100920A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2005070043A3 (fr) Methode pour traiter les cancers non melaniques avec paba
WO2006028963A3 (fr) Composes heterocycliques substitues et leurs utilisations
WO2007109093A3 (fr) Derives de pyrazolo[1,5-a]pyrimidine et procedes d'utilisation de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006709496

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006709496

Country of ref document: EP